Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Angiogenesis
Published in: Angiogenesis 1/1999

01-03-1999

Zinc ligand-disrupted recombinant human Endostatin: Potent inhibition of tumor growth, safety and pharmacokinetic profile

Authors: B. Kim Lee Sim, William E. Fogler, Xin Hua Zhou, Hong Liang, John W. Madsen, Kieu Luu, Michael S. O'Reilly, Joseph E. Tomaszewski, Anne H. Fortier

Published in: Angiogenesis | Issue 1/1999

Login to get access
Metadata
Title
Zinc ligand-disrupted recombinant human Endostatin: Potent inhibition of tumor growth, safety and pharmacokinetic profile
Authors
B. Kim Lee Sim
William E. Fogler
Xin Hua Zhou
Hong Liang
John W. Madsen
Kieu Luu
Michael S. O'Reilly
Joseph E. Tomaszewski
Anne H. Fortier
Publication date
01-03-1999
Publisher
Kluwer Academic Publishers
Published in
Angiogenesis / Issue 1/1999
Print ISSN: 0969-6970
Electronic ISSN: 1573-7209
DOI
https://doi.org/10.1023/A:1009058931769

Other articles of this Issue 1/1999

Angiogenesis 1/1999 Go to the issue

OriginalPaper

From the Editor's desk

OriginalPaper

Expression and assembly of the angiogenic marker B-fibronectin by endothelial cells in vitro: Regulation by confluency

OriginalPaper

Obituary

OriginalPaper

Regulation of angiogenesis and endothelial cell motility by matrix-bound fibroblasts

OriginalPaper

Commentary on zinc ligand-disrupted recombinant human Endostatin

OriginalPaper

The urokinase plasminogen activator system in cancer: Implications for tumor angiogenesis and metastasis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits